COMPANY

BioCardia

HQ: Sunnyvale, CA source · biocardia.com ↗ · West Coast

FDA-cleared device company Clinical Phase 2

Our four clinical stage marrow derived cell therapy programs include autologous (using a patient's own cells) and allogeneic (using cells manufactured from patient donors) approaches. From company website Source · Oct 12, 2026

Keywords: cell therapy Systolic Heart Failure Ischemic Heart Failure Human ARDS Refractory Angina Chronic Myocardial Ischemia Ventricular Dysfunction Myocardial Infarction Autologous cell therapy

Location: Sunnyvale, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$6.0MRaised (2 yrs)6Trials (company is sponsor)2NIH grants

Timeline

Jan 4, 2026 Trial start Phase 1: AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial source ↗
Sep 18, 2025 Raise Follow-on offering: $6M (total, as published), announced Sep 18, 2025. Source: company release on GlobeNewswire. source ↗
Aug 13, 2025 Partnership Partnership / licensing announced Aug 13, 2025. Source: SEC filing. source ↗
Aug 1, 2024 Trial start Not phased (device or behavioral study): CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction source ↗
Aug 23, 2023 Trial start Phase 1/Phase 2: Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells source ↗
Jun 30, 2021 Trial start Not phased (device or behavioral study): CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial source ↗
2016-12 Trial start Phase 3: CardiAMP™ Cell Therapy for Heart Failure Trial source ↗
2005-12 Trial start Phase 1: Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1/Phase 2 · Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells · NCT05925608
Apr 1, 2027 (ESTIMATED) · Not phased · CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction · NCT06258447

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $6.0M. Last 2 years.

Sep 18, 2025 Follow-on offering: $6M (total, as published), announced Sep 18, 2025. Source: company release on GlobeNewswire. source ↗
Aug 13, 2025 Partnership / licensing announced Aug 13, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06258447	CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction	Not phased (device or behavioral study)	Recruiting	Aug 1, 2024	Apr 1, 2027 (estimated)
NCT05491681	AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial	Phase 1	Withdrawn	Jan 4, 2026	Jan 4, 2026 (actual)
NCT03455725	CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial	Not phased (device or behavioral study)	Active, not recruiting	Jun 30, 2021	Feb 19, 2025 (actual)
NCT05925608	Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells	Phase 1/Phase 2	Active, not recruiting	Aug 23, 2023	2026-12 (estimated)
NCT02438306	CardiAMP™ Cell Therapy for Heart Failure Trial	Phase 3	Completed	2016-12	2025-02 (actual)
NCT00507468	Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone	Phase 1	Completed	2005-12	2009-03 (actual)

NIH awards 2

Annual award amounts. Total $237K.

May 31, 2011 NIH award 1R43HL097775-01A2 FY2011: $136,593 awarded for that fiscal year; activity R43 (SBIR); PI ROUY, DIDIER B; recipient as written: BIOCARDIA, INC., Sunnyvale, CA. Cell retention and biodistribution after transe source ↗
Jun 4, 2009 NIH award 1R43EB008925-01A1 FY2009: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI ROUY, DIDIER B; recipient as written: BIOCARDIA, INC., Sunnyvale, CA. Endomyocardial Catheter Delivery of Artificial source ↗